Jazz Pharmaceuticals Shareholders Elect Laura Hamill to the Company's Board of Directors at Annual General Meeting
Jazz Pharmaceuticals (Nasdaq: JAZZ) announced the election of Laura Hamill to its Board of Directors at the Annual General Meeting. Ms. Hamill, a 35-year pharmaceutical industry veteran, brings extensive executive leadership and global commercial operations expertise. Shareholders also re-elected Kenneth O'Keefe and Mark Smith, while Patrick Kennedy was appointed earlier this year.
Ms. Hamill previously served as Executive Vice President of Worldwide Commercial Operations at Gilead Sciences and held various executive positions at Amgen Inc. She currently serves on the boards of Y-mAbs Therapeutics, BB Biotech, and Unchained Labs. The election reflects Jazz's focus on Board renewal, with five new directors appointed in the past five years. Peter Gray and Catherine Sohn have retired from the Board, which now comprises twelve directors.
Jazz Pharmaceuticals (Nasdaq: JAZZ) ha annunciato l'elezione di Laura Hamill nel suo Consiglio di Amministrazione durante l'Assemblea Generale Annuale. La signora Hamill, veterana dell'industria farmaceutica con 35 anni di esperienza, porta con sé una vasta esperienza nella leadership esecutiva e nelle operazioni commerciali globali. Gli azionisti hanno anche rieletto Kenneth O'Keefe e Mark Smith, mentre Patrick Kennedy è stato nominato all'inizio di quest'anno.
La signora Hamill ha precedentemente ricoperto il ruolo di Vice Presidente Esecutivo delle Operazioni Commerciali Mondiali presso Gilead Sciences e ha ricoperto varie posizioni esecutive in Amgen Inc. Attualmente, fa parte dei consigli di amministrazione di Y-mAbs Therapeutics, BB Biotech e Unchained Labs. L'elezione riflette l'attenzione di Jazz per il rinnovamento del Consiglio, con cinque nuovi direttori nominati negli ultimi cinque anni. Peter Gray e Catherine Sohn si sono ritirati dal Consiglio, che ora è composto da dodici direttori.
Jazz Pharmaceuticals (Nasdaq: JAZZ) anunció la elección de Laura Hamill a su Junta Directiva en la Junta General Anual. La Sra. Hamill, veterana de 35 años en la industria farmacéutica, aporta una amplia experiencia en liderazgo ejecutivo y operaciones comerciales globales. Los accionistas también reelegieron a Kenneth O'Keefe y Mark Smith, mientras que Patrick Kennedy fue nombrado a principios de este año.
La Sra. Hamill se desempeñó anteriormente como Vicepresidenta Ejecutiva de Operaciones Comerciales Globales en Gilead Sciences y ocupó varios puestos ejecutivos en Amgen Inc. Actualmente forma parte de las juntas de Y-mAbs Therapeutics, BB Biotech y Unchained Labs. La elección refleja el enfoque de Jazz en la renovación de la Junta, con cinco nuevos directores nombrados en los últimos cinco años. Peter Gray y Catherine Sohn se han retirado de la Junta, que ahora consta de doce directores.
Jazz Pharmaceuticals(Nasdaq: JAZZ)는 연례 총회에서 Laura Hamill을 이사회에 선출했다고 발표했습니다. Hamill 씨는 제약 산업에서 35년의 경력을 가진 베테랑으로, 광범위한 임원 리더십과 글로벌 상업 운영 전문성을 보유하고 있습니다. 주주들은 Kenneth O'Keefe와 Mark Smith를 다시 선출하였고, Patrick Kennedy는 올해 초에 임명되었습니다.
Hamill 씨는 이전에 Gilead Sciences의 전 세계 상업 운영 부사장으로 재직했으며, Amgen Inc.에서 여러 임원 직책을 맡았습니다. 현재 그녀는 Y-mAbs Therapeutics, BB Biotech 및 Unchained Labs의 이사회에서 활동하고 있습니다. 이 선출은 Jazz가 이사회의 갱신에 집중하고 있음을 반영하며, 지난 5년 동안 5명의 새로운 이사가 임명되었습니다. Peter Gray와 Catherine Sohn은 이사회에서 은퇴하였으며, 현재 이사회는 12명의 이사로 구성되어 있습니다.
Jazz Pharmaceuticals (Nasdaq: JAZZ) a annoncé l'élection de Laura Hamill à son Conseil d'Administration lors de l'Assemblée Générale Annuelle. Mme Hamill, vétérane de 35 ans dans l'industrie pharmaceutique, apporte une vaste expérience en leadership exécutif et en opérations commerciales mondiales. Les actionnaires ont également réélu Kenneth O'Keefe et Mark Smith, tandis que Patrick Kennedy a été nommé plus tôt cette année.
Mme Hamill a précédemment été Vice-Présidente Exécutive des Opérations Commerciales Mondiales chez Gilead Sciences et a occupé divers postes exécutifs chez Amgen Inc. Elle est actuellement membre des conseils d'administration de Y-mAbs Therapeutics, BB Biotech et Unchained Labs. L'élection reflète l'accent mis par Jazz sur le renouvellement du Conseil, avec cinq nouveaux directeurs nommés au cours des cinq dernières années. Peter Gray et Catherine Sohn se sont retirés du Conseil, qui compte désormais douze membres.
Jazz Pharmaceuticals (Nasdaq: JAZZ) gab die Wahl von Laura Hamill in seinen Vorstand während der Hauptversammlung bekannt. Frau Hamill, eine 35-jährige Veteranin der Pharmaindustrie, bringt umfassende Erfahrung in der Führung und globalen kommerziellen Operationen mit. Die Aktionäre wählten auch Kenneth O'Keefe und Mark Smith wieder, während Patrick Kennedy Anfang dieses Jahres ernannt wurde.
Frau Hamill hatte zuvor die Position der Executive Vice President für weltweite kommerzielle Operationen bei Gilead Sciences inne und bekleidete verschiedene Führungspositionen bei Amgen Inc. Derzeit ist sie im Vorstand von Y-mAbs Therapeutics, BB Biotech und Unchained Labs tätig. Die Wahl spiegelt den Fokus von Jazz auf die Erneuerung des Vorstands wider, wobei in den letzten fünf Jahren fünf neue Direktoren ernannt wurden. Peter Gray und Catherine Sohn sind aus dem Vorstand ausgeschieden, der nun aus zwölf Direktoren besteht.
- Election of Laura Hamill, bringing 35 years of pharmaceutical industry experience to the Board
- Continued focus on Board renewal with five new directors in the past five years
- Strengthened Board expertise in commercial growth and global operations
- None.
Ms. Hamill brings extensive experience and proven leadership focused on commercial growth and shareholder value
"We are delighted to welcome Laura to the Board," said Bruce Cozadd, chairperson and CEO, Jazz Pharmaceuticals. "Her extensive commercial and industry experience and well-established track record with dynamic, multi-national companies is exceptionally aligned with Jazz's focus on creating value for shareholders. I feel certain Laura's expertise will complement the capabilities of the existing Jazz Board as we aim to transform the lives of patients and their families."
Ms. Hamill most recently held the position of Executive Vice President, Worldwide Commercial Operations, for Gilead Sciences, Inc. from 2018 to 2019. From 2002 to 2018, Ms. Hamill served in various executive management positions at Amgen Inc., including Senior Vice President,
"I am impressed by the global talent in the organization driving the strength of Jazz's business," said Ms. Hamill. "I look forward to the opportunity to work alongside my Board colleagues and the company's management to help guide the company's future growth in order to deliver sustained value to our shareholders and meaningful impact for patients."
As previously disclosed and effective today, Peter Gray and Catherine Sohn, Pharm.D., have retired from the Jazz Board, which now will be comprised of twelve directors, five of whom have been appointed in the past five years.
"I want to thank Cathy and Peter for their outstanding service and dedication to Jazz," Mr. Cozadd added. "They both have been valued members of the Jazz Board and instrumental in our transformation and continued growth. We have been grateful for their commitment and wish them well as they transition off the Board."
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases—often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in
Contacts:
Jazz Media Contact:
Kristin Bhavnani
Head of Global Strategic Brand Engagement
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com
Jazz Investor Contact:
Andrea N. Flynn, Ph.D.
Vice President, Head, Investor Relations
Jazz Pharmaceuticals plc
investorinfo@jazzpharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-shareholders-elect-laura-hamill-to-the-companys-board-of-directors-at-annual-general-meeting-302206714.html
SOURCE Jazz Pharmaceuticals plc
FAQ
Who is the new Board member elected to Jazz Pharmaceuticals (JAZZ)?
What is Laura Hamill's background before joining Jazz Pharmaceuticals (JAZZ) Board?
How many directors are now on the Jazz Pharmaceuticals (JAZZ) Board after recent changes?
When did Jazz Pharmaceuticals (JAZZ) hold its Annual General Meeting in 2024?
